• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery

    Injectable Drug Delivery Trends

    Oral Solids: Market & Technology Trends
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Alcami

    Adare Pharma Solutions

    Emergent BioSolutions

    Federal Equipment Company
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    PCI Pharma Services

    Alcami

    Emergent BioSolutions

    Federal Equipment Company
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Getting PAT into Bioprocessing CMOs

    The Good, the Bad, and the “Whatever”

    Getting PAT into Bioprocessing CMOs
    Related CONTENT
    • Mogene
    • Softweb Solutions
    • Vetio Animal Health
    • Risk-Based Monitoring
    • The Orphan Promise
    Emil W. Ciurczak, DoraMaxx Consulting06.13.19
    Ever since I started doing near-infrared spectroscopy (NIRS), circa 1983, I have had an eye towards performing analyses in the warehouse and, later, in the process line. For decades, I had been performing “traditional” analyses: HPLC, GLC, TLC, polarography, thermal analysis, flame emission, UV/Vis, Mid-Range IR, etc. All are excellent methodologies, but all lab-based and used for AFTER-PRODUCTION analysis. These may be used to assure that an already finished product passes specifications, but, for all intents and purposes, cannot be used to control a process or tell where it may have gone OOS. Now, it appeared I had a tool that could be adapted to real-time analyses as is true for newer arrivals Raman and LIF, or light-induced fluorescence. My first use was in 100% qualification of all incoming raw materials (1984-5), but I needed to wait a few years for a chance to monitor a production process.

    In 1989, I suggested that any blending process (powder or liquid) could be followed by simply inserting a (NIR) probe, scanning at regular (short) intervals, and, when there are tiny or no further changes, the mixing process is complete. I was challenged by a manager at NIRSystems to “put up or shut up,” so I did the first blending study. I used a simple four-component system in a small vessel, rotating and stopping at regular intervals. Each time the “blender stopped,” I inserted a NIR probe at several depths and locations, repeating the procedure until the math (Principal Components) showed there to be no further changes. It was blended as well as possible. Clearly, later, wireless NIR units are true process tools, but we had to do some feasibility studies first.

    Then, a few years later, I got an opportunity to work on a process, in real time. In 1992, the plant engineer at Merck (West Point, PA) allowed me to chop a hole in the hopper of a production encapsulating machine and insert a NIR probe. I had been trying to monitor, with hopes of controlling, a solid dosage from production line. I was able to monitor the content uniformity of the granulation, enabling the process engineer to stop, should the content drop below a minimum or become enriched.

    In 2002, Ajaz Hussain convened a series of meetings/hearings and mini-conferences to present the technical capabilities and methodologies to monitor and control processes in real time. This led to the issuance of the PAT Guidance in 2004. The initial draft and subsequent final version were entirely based on small molecule, solid dosage forms. The U.S. FDA designed the PAT Guidance for small molecules for a number of good reasons:
    1. There is nearly zero chemistry involved (wetting and drying is hardly “real” chemistry), merely physical mixing. Any complex, chemical reactions all take place at the API synthesis step, at a different location, nearly always before the “process” of dosage form manufacture is performed.
    2. The use of in-line/at-line instrumentation is largely an extension of current laboratory equipment. Spectroscopy and physical methods are already familiar, only the need for faster sampling and analysis times, so operators/analysts have, at some level, have some familiarity with the newer equipment.
    3. The personnel roster of a small-molecule manufacturer includes more traditional chemists (organic, R&D, and QC) and numerous types of engineers, so the statistics/algorithms of process chemistry (multi-variate analyses) are not too foreign.
    4. Since the chemistry of the API was established prior to formulation of the dosage form, nearly all the production problems with solid dosage forms were embedded in the formulation, blending, and formation of the dosage forms: all physical and material issues.

    Another pragmatic reason was that the vast majority of marketed drugs (bulk sales = profits) were based on small molecules, while most biopharma companies were either new (start-ups) or still in the “R&D” stages, so there weren’t as many large molecule products in existence. But, as the big-money, super-drug supply line has dried a touch in recent years, there have been a few changes in the weather:
    1. The consequence of the “good old days” of blockbuster after blockbuster being introduced was the growth of large Pharma, largely through M&A (mergers and acquisitions). Larger facilities were great during growth periods, but, like licking one’s lips when chapped, it felt good, but, in the long run, was deleterious.
    2. The large overhead of maintaining huge “empires” (I believe, at the peak of growth, Pfizer had 82 sites), could not be maintained with “normal” sales of “merely” several hundred million in sales. Outsourcing was inevitable.
    3. With fewer small molecule NDEs (new drug entities), most of the big houses have been turning to macromolecules: i.e., biologics.

    What does this mean in terms of relationships with CMOs and CROs and their clients (sponsors)? Several things come to mind:
    1. Since most big houses are in the early stages of producing potential blockbusters (indeed, many are still in the R&D stage, with no marketed products), there is a paucity of contract companies capable of cranking out large numbers of biological products.
    2. In fact, few big BioPharma companies have true PAT and QbD in play. That makes it ever so difficult to “transfer” a PAT program to a contract site and, for that matter, generics with less available resources will have trouble implementing one.
    3. The vast majority of CMOs are set up to generate solid dosage forms, so many of them will be starting at zero, with a steep and high learning curve. Let alone having bio-personnel on staff.
    4. Even parts of big Pharma need intensive training to adapt PAT/QbD to their bioprocess lines.

    Now we can address the difficulties in beginning a (true) PAT/QbD program in both large and small companies. First, we need to assume that there is a staff on-site, familiar with the bioprocess (fermentation, clean-up, etc.), namely, biochemists, biologists, molecular biologists and chromatographers. That means that there is a paucity (as from above) of “traditional” personnel in the biopharma divisions/CMOs: analytical chemists, process engineers, material scientists, Chemometricians, etc.

    This means the actual training of biotech personnel will have to be modified. For companies rich in analytical chemists (R&D, development, and QC), pharmacists, and process engineers), an introductory course with some examples is sufficient. For a bioprocess site a different approach is needed:
    1. A deeper explanation of why each step needs to be monitored and controlled needs to be generated.
    2. Since there is little baseline information about the economics of this “newish” industry, merely using the “saves money” argument (as with tablet/capsule production) rings hollow. Many of these companies either do not make a profit/have a finished product or have one that is raking in money, such that savings are the last thing on their minds.
    3. Since biopharma companies are heavily weighted to life sciences, simply showing previous applications of PAT instruments will have less than full success. If no one in the audience/class has ever seen, let alone used a NIR, Raman, LIBS (LASER-induced breakdown spectroscopy), or LIF (light-induced fluorescence), merely showing some examples means little or nothing.
    4. All the FDA, EMA, and ICH Guidances mean little to a company/staff that has never (or seldom) been under Agency scrutiny, so these need to be placed in context; merely reading them will not suffice.
    5. Concepts such as QRM (quality risk management) and DoE (design of experiment) need more than simple explanations. The best approach, which I have done in Europe, is to choose (have them choose) a process/product as an example. What I did was make a series of PowerPoint slides, featuring their process. Shown as a block diagram, each step shows the chemistry (OK, “biology”), components, and potential monitor/control equipment, as well as software/algorithms used; and don’t forget to show how to validate each step.
    6. Stress and explain the personnel changes and training that will need to happen to generate a working PAT/QbD program:
    a. QA personnel will need (offsite?) training on, at a minimum, the ICH guidances: Q8 through Q11. They are both the conscience of the labs and production and the interface with the Agencies, so they need more than a “working knowledge” of the guidances.
    b. An enhanced IT department is a need. Granted, biological work requires a lot of statistics for clinical work and reaction overview, but multivariate analyses that will take place in a bioprocess PAT program will need people conversant with Chemometrics and process control algorithms.
    c. Hardware and an instrument group will need to be added. Process instrumentation is beyond the comfort zone of lab chemists (especially biochemists) and utterly foreign to the bioprocess people. Just calibration, maintaining, and repairing the hardware will be a new frontier for the company… and the current personnel will not likely be equipped (or emotionally prepared) to deal with utterly different hardware and technologies.
    d. AR&D and QC personnel, familiar with these newer technologies. They will need to find the technologies, specify the equipment, determine the location for them, when and how often to sample the process, how to model the data, and generate the equation to control a process.
    e. These same people will need to work  with the Chemometricians to maintain and update any multivariate equations being used to monitor and control the process. (And, don’t forget that need to explain the work to QA and the Agency.)

    So, in short, bringing a successful PAT/QbD program to biopharma is a horse of a different feather. It will be new and different, but very, very worthwhile. This will be a true case for the need of massive cooperation between the innovators and the contract manufacturers.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • software
    • bioprocessing
    • blending
    • biopharma companies
    Suggested For You
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Risk-Based Monitoring Risk-Based Monitoring
    The Orphan Promise The Orphan Promise
    Lilly Lilly's CYRAMZA Gains Fifth Indication
    The Coming Revolution of Personalized Medicine The Coming Revolution of Personalized Medicine
    Swissfillon Completes Successful FDA Inspection Swissfillon Completes Successful FDA Inspection
    Merck to Restructure Manufacturing Ops Merck to Restructure Manufacturing Ops
    Merck & NJII Receive NIIMBL Award Merck & NJII Receive NIIMBL Award
    Pharmaceutical Excipients Trends Pharmaceutical Excipients Trends
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review
    PCI Bolsters Supply Chain Leadership PCI Bolsters Supply Chain Leadership
    Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

    Related Columns

    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18

    • Bioanalytical Services

      21st Century Technologies for Bioprocessing Control

      A closer look at the manufacture of biomolecules
      Emil W. Ciurczak, DoraMaxx Consulting 06.06.17

    • Bioanalytical Services
      Current Trends in Analytical Testing

      Current Trends in Analytical Testing

      Improved analytical methods continues to be a current need for nearly every aspect of biopharma manufacturing
      Eric S. Langer, BioPlan Associates 05.09.17


    • Analytical Services | Bioanalytical Services | Chemistry | Laboratory Testing

      Hyperspectral Imaging

      It’s not just for the Big Boys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 11.09.16

    • Analytical Services | Bioanalytical Services | R&D

      Raman Spectroscopy

      Rapidly becoming the CRO/CMO’s best friend
      Emil W. Ciurczak, DoraMaxx Consulting 10.13.16

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15


    • Analytical Services | APIs | Bioanalytical Services | Bioassay Development | Capsules | Excipients | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Laboratory Testing | Logistics | Lyophilization | Microbiology | Process Development | R&D | Toxicology | Validation

      Build It and He Will Come

      Updated labs and personnel help build business
      Emil W. Ciurczak, DoraMaxx Consulting 06.02.15

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • WuXi AppTec Completes OXGENE Acquisition
    • Arcline Investment Acquires ChargePoint Technology
    Breaking News
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    • Four Female Leaders Appointed to Cell & Gene CDMO
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Gadot Biochemical Launches New Magnesium Ingredients
    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Benjamin Moore Launches COMMAND
    AOC Announces EMEA Price Increase
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Philips, Disney Join Forces to Reduce Childrens' MRI Anxiety
    Philips, Disney Partner to Improve MRI Experience for Children
    FDA OKs Asensus' Senhance for General Surgery
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Innoforce and dMed Enter Development Collaboration
    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    Four Female Leaders Appointed to Cell & Gene CDMO
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    P&G Makes Progress Toward Packaging Circularity in Europe
    Coty Partners with LanzaTech to Introduce Sustainable Ethanol
    Remembering Fred Segal, a Trendsetting Retail Pioneer
    Happi

    Latest Breaking News From Happi

    Coty Partners with LanzaTech to Reduce Its Environmental Impact
    Waterless Beauty, Simplified Routines Shape Clean Beauty at Whole Foods
    Redken Updates Packaging, Adds New Products
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Ashland announces PSA price hike in North America
    Arrow Systems and Sihl form flexible packaging partnership
    Flint Group Packaging announces global price increase
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Joa Announces Expandable Absorbent Core Wrap Solution
    Principle Business Enterprises Celebrates 60 Years
    Mann+Hummel Invests in Pamlico Air
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Spinal Elements Relaunches the Luna XD and Orbit Systems
    Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew
    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login